Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solabegron Phase 2b in OAB
NCT03475706Phase 2Completed
- Sponsor
- Velicept Therapeutics
- Start
- Feb 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Solabegron in overactive bladder (OAB), sponsored by Velicept Therapeutics. Started Feb 2018; status: completed.
02
Drugs
Solabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT03475706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03475706.